Skip to main content
. 2017 Oct 10;8(70):114722–114735. doi: 10.18632/oncotarget.21773

Figure 4. Imaging flow cytometry of CD9+/GFAP+/SVN+ exosomes in patients whose tumors progressed early (8.0-25.1 weeks) following initial vaccination.

Figure 4

CD9+/GFAP+/SVN+ exosomes at baseline (i.e. prior to first dose of vaccine) are shown in the left column, CD9+/GFAP+/SVN+ exosomes obtained from serum 8-24 weeks after first dose of vaccine (middle column) at the time of tumor progression, and in one patient (#7) at 25 weeks (right panel).

HHS Vulnerability Disclosure